Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lene Sofie Granfeldt Oestgaard"'
Autor:
Jan Maxwell Nørgaard, Susanne Oksbjerg Dalton, Kirsten Groenbaek, Tine Bichel Lauritsen, Lene Sofie Granfeldt Oestgaard
Publikováno v:
Blood. 138:4670-4670
Background: Five-year overall survival for patients with myelodysplastic syndromes (MDS) is around 30%. Adverse prognostic factors include advancing age, higher blast cell percentage, poor risk cytogenetics, two or more cytopenias, high burden of com
Autor:
Mette Nørgaard, Marianne Tang Severinsen, Bruno C. Medeiros, Lene Sofie Granfeldt Oestgaard, Claus Werenberg Marcher, Ulrik Malthe Overgaard, Claudia Schöllkopf, Michael Tøstesen, Jan Maxwell Nørgaard
Publikováno v:
Tostesen, M B, Norgaard, J M, Nørgaard, M, Medeiros, B C, Marcher, C W, Overgaard, U M, Schöllkopf, C, Severinsen, M T & Oestgaard, L S G 2018, ' Longer Distance to a Specialized Treatment Center Does Not Adversely Affect Access to Treatment or Outcome in Acute Myeloid Leukemia : A National Population-Based Cohort Study ', Blood, vol. 132, no. Suppl. 1, pp. 613 . https://doi.org/10.1182/blood-2018-99-110922
Buch Tostesen, M, Norgaard, J M, Nørgaard, M, Medeiros, B C, Marcher, C W, Overgaard, U M, Schöllkopf, C, Severinsen, M T & Østgård, L S G 2018, ' Longer Distance to a Specialized Treatment Center Does Not Adversely Affect Access to Treatment or Outcome in Acute Myeloid Leukemia: A National Population-Based Cohort Study ', Blood, vol. 132, no. Suppl. 1, 613 . https://doi.org/10.1182/blood-2018-99-110922
Buch Tostesen, M, Norgaard, J M, Nørgaard, M, Medeiros, B C, Marcher, C W, Overgaard, U M, Schöllkopf, C, Severinsen, M T & Østgård, L S G 2018, ' Longer Distance to a Specialized Treatment Center Does Not Adversely Affect Access to Treatment or Outcome in Acute Myeloid Leukemia: A National Population-Based Cohort Study ', Blood, vol. 132, no. Suppl. 1, 613 . https://doi.org/10.1182/blood-2018-99-110922
BACKGROUND Treatment of acute myeloid leukemia (AML) is widely centralized at specialized centers. Longer distances to a specialized treatment facility may affect patients' access to curative-intended treatment and ultimately survival. Few studies ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25521ebf0ffff39a7329774c002d52b
https://vbn.aau.dk/da/publications/1f2901b2-e22f-418d-9f0d-fc6a0827a6a0
https://vbn.aau.dk/da/publications/1f2901b2-e22f-418d-9f0d-fc6a0827a6a0
Autor:
Christian Fynbo Christiansen, Cecilie Velsoe Maeng, Kathleen D. Liu, Lene Sofie Granfeldt Oestgaard
Publikováno v:
Blood. 134:4783-4783
Significance Patients with acute myeloid leukemia (AML) are at high risk of critical illness requiring admission to the intensive care unit (ICU) due to both disease- and treatment-related complications. A better understanding of risk factors for ICU
Autor:
Christian Fynbo Christiansen, Kathleen D. Liu, Cecilie Velsoe Maeng, Lene Sofie Granfeldt Oestgaard
Publikováno v:
Blood. 134:334-334
Introduction The mortality in non-promyelocytic acute myeloid leukemia (AML) has decreased as a result of improved supportive care, allowing for more aggressive treatment options, including increased use of allogeneic stem cell transplantation. To in
Autor:
Marianne Tang Severinsen, Jan Maxwell Nørgaard, Lone S. Friis, Eigil Kjeldsen, Lars Kjeldsen, Henrik Sengeloev, Mette Holm, Ove Juul Nielsen, Hans Erik Johnsen, Morten K. Jensen, Olav J. Bergmann, Lene Sofie Granfeldt Oestgaard
Publikováno v:
Blood. 118:2003-2003
Abstract 2003 The prognosis of patients suffering from AML with manifestations of accompanying extramedullary leukemia (EML) including myeloid sarcoma (MS) compared to that of AML patients not exhibiting EML manifestations is still an open question a
Autor:
Preben Johansen, Mette K. Andersen, Lene Sofie Granfeldt Oestgaard, Joergen Kristensen, Maria Kallenbach, Birgitte Preiss, Jan Maxwell Nørgaard, Knud Bendix, Peter de Nully Brown, Inge Høgh Dufva, Gitte Kerndrup, Susanne Timshel
Publikováno v:
Blood. 118:3586-3586
Abstract 3586 The prognosis of leukemia patients suffering from secondary AML (sAML) compared to that of patients with de novo AML is dismal. The group of sAMLs is heterogeneous and includes AML arising from an antecedent myelodysplastic (MDS) or mye